Plain-English translation of NCT03412877 on ClinicalTrials.gov ↗ ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a personalized cancer treatment approach. Doctors will take immune cells from your blood, genetically engineer them in the laboratory to recognize and attack your specific cancer, and then infuse them back into your body. The goal is to see if these customized cells can shrink or eliminate advanced cancers that have stopped responding to standard treatments.
Most advanced cancers eventually become resistant to chemotherapy and other standard treatments, leaving patients with few options. This treatment exists to explore whether personalized immune cells—trained to recognize the unique mutations in each patient's cancer—can offer a new way to fight these resistant cancers.
You likely qualify if…
You likely don't qualify if…
If you enroll, doctors will first remove some of your immune cells through a blood sample. These cells are then sent to a laboratory where they are genetically modified to recognize your cancer. While the cells are being prepared (which takes several weeks), you will receive chemotherapy to prepare your body. Once ready, you will receive an infusion of your engineered cells, followed by a medication called to help activate them. Some participants will also receive pembrolizumab, an immunotherapy drug, alongside the cell infusion. You will have frequent hospital visits for monitoring, blood tests, and imaging scans to track how well the treatment is working.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States